nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—HTR1D—meninx—malignant glioma	0.0644	0.102	CbGeAlD
Lisuride—HTR1B—dura mater—malignant glioma	0.0612	0.0971	CbGeAlD
Lisuride—HTR1D—dura mater—malignant glioma	0.0592	0.094	CbGeAlD
Lisuride—HTR2C—choroid plexus—malignant glioma	0.0499	0.0792	CbGeAlD
Lisuride—DRD3—telencephalic ventricle—malignant glioma	0.0263	0.0417	CbGeAlD
Lisuride—HTR2A—choroid plexus—malignant glioma	0.025	0.0397	CbGeAlD
Lisuride—DRD1—telencephalic ventricle—malignant glioma	0.0188	0.0299	CbGeAlD
Lisuride—HTR1B—telencephalic ventricle—malignant glioma	0.0152	0.0242	CbGeAlD
Lisuride—HTR1D—telencephalic ventricle—malignant glioma	0.0148	0.0234	CbGeAlD
Lisuride—HTR2C—telencephalic ventricle—malignant glioma	0.0146	0.0232	CbGeAlD
Lisuride—HTR2A—cerebellar cortex—malignant glioma	0.0126	0.02	CbGeAlD
Lisuride—HTR1A—telencephalic ventricle—malignant glioma	0.0123	0.0195	CbGeAlD
Lisuride—DRD2—telencephalic ventricle—malignant glioma	0.0111	0.0176	CbGeAlD
Lisuride—HTR2A—pons—malignant glioma	0.00891	0.0141	CbGeAlD
Lisuride—HTR2A—vertebral column—malignant glioma	0.00884	0.014	CbGeAlD
Lisuride—HTR1B—blood vessel—malignant glioma	0.00754	0.012	CbGeAlD
Lisuride—HTR2A—telencephalic ventricle—malignant glioma	0.00733	0.0116	CbGeAlD
Lisuride—HTR1D—blood vessel—malignant glioma	0.0073	0.0116	CbGeAlD
Lisuride—Pulmonary fibrosis—Carmustine—malignant glioma	0.00704	0.0972	CcSEcCtD
Lisuride—Pulmonary fibrosis—Temozolomide—malignant glioma	0.0068	0.0939	CcSEcCtD
Lisuride—HTR2A—pineal body—malignant glioma	0.00636	0.0101	CbGeAlD
Lisuride—DRD5—telencephalon—malignant glioma	0.00591	0.00938	CbGeAlD
Lisuride—DRD1—brainstem—malignant glioma	0.00509	0.00808	CbGeAlD
Lisuride—ADRA1D—telencephalon—malignant glioma	0.00474	0.00752	CbGeAlD
Lisuride—DRD1—telencephalon—malignant glioma	0.00452	0.00717	CbGeAlD
Lisuride—HTR1B—brainstem—malignant glioma	0.00412	0.00655	CbGeAlD
Lisuride—DRD4—brain—malignant glioma	0.00405	0.00643	CbGeAlD
Lisuride—HTR1D—brainstem—malignant glioma	0.00399	0.00634	CbGeAlD
Lisuride—HTR2C—brainstem—malignant glioma	0.00395	0.00628	CbGeAlD
Lisuride—HTR2A—endothelium—malignant glioma	0.00393	0.00625	CbGeAlD
Lisuride—HTR1B—telencephalon—malignant glioma	0.00366	0.00581	CbGeAlD
Lisuride—HTR2A—blood vessel—malignant glioma	0.00363	0.00576	CbGeAlD
Lisuride—DRD3—central nervous system—malignant glioma	0.00358	0.00569	CbGeAlD
Lisuride—HTR1D—telencephalon—malignant glioma	0.00354	0.00562	CbGeAlD
Lisuride—HTR2C—telencephalon—malignant glioma	0.00351	0.00557	CbGeAlD
Lisuride—ADRB1—telencephalon—malignant glioma	0.00344	0.00547	CbGeAlD
Lisuride—DRD5—central nervous system—malignant glioma	0.00336	0.00533	CbGeAlD
Lisuride—HTR1A—brainstem—malignant glioma	0.00333	0.00528	CbGeAlD
Lisuride—HTR2B—telencephalon—malignant glioma	0.0033	0.00523	CbGeAlD
Lisuride—DRD1—midbrain—malignant glioma	0.00324	0.00515	CbGeAlD
Lisuride—DRD2—brainstem—malignant glioma	0.00301	0.00477	CbGeAlD
Lisuride—HTR1A—telencephalon—malignant glioma	0.00295	0.00469	CbGeAlD
Lisuride—DRD2—retina—malignant glioma	0.0029	0.00461	CbGeAlD
Lisuride—DRD3—brain—malignant glioma	0.00285	0.00452	CbGeAlD
Lisuride—HTR2C—medulla oblongata—malignant glioma	0.00276	0.00438	CbGeAlD
Lisuride—ADRA1B—central nervous system—malignant glioma	0.00275	0.00437	CbGeAlD
Lisuride—ADRA1D—central nervous system—malignant glioma	0.00269	0.00428	CbGeAlD
Lisuride—DRD2—telencephalon—malignant glioma	0.00267	0.00424	CbGeAlD
Lisuride—DRD5—brain—malignant glioma	0.00267	0.00423	CbGeAlD
Lisuride—HTR1B—midbrain—malignant glioma	0.00263	0.00417	CbGeAlD
Lisuride—ADRA2C—telencephalon—malignant glioma	0.00259	0.00412	CbGeAlD
Lisuride—DRD1—central nervous system—malignant glioma	0.00257	0.00408	CbGeAlD
Lisuride—HTR1B—spinal cord—malignant glioma	0.00256	0.00407	CbGeAlD
Lisuride—HTR1D—midbrain—malignant glioma	0.00254	0.00404	CbGeAlD
Lisuride—HTR2C—midbrain—malignant glioma	0.00252	0.004	CbGeAlD
Lisuride—HTR2C—spinal cord—malignant glioma	0.00246	0.0039	CbGeAlD
Lisuride—ADRA1B—brain—malignant glioma	0.00219	0.00347	CbGeAlD
Lisuride—HTR2A—embryo—malignant glioma	0.00216	0.00344	CbGeAlD
Lisuride—ADRA1D—brain—malignant glioma	0.00214	0.0034	CbGeAlD
Lisuride—HTR1A—midbrain—malignant glioma	0.00212	0.00337	CbGeAlD
Lisuride—HTR1B—central nervous system—malignant glioma	0.00208	0.0033	CbGeAlD
Lisuride—ADRA2A—telencephalon—malignant glioma	0.00207	0.00329	CbGeAlD
Lisuride—HTR1A—spinal cord—malignant glioma	0.00207	0.00328	CbGeAlD
Lisuride—ADRA2C—medulla oblongata—malignant glioma	0.00204	0.00324	CbGeAlD
Lisuride—DRD1—brain—malignant glioma	0.00204	0.00324	CbGeAlD
Lisuride—Dehydration—Temozolomide—malignant glioma	0.00202	0.0279	CcSEcCtD
Lisuride—HTR1D—central nervous system—malignant glioma	0.00201	0.0032	CbGeAlD
Lisuride—HTR2C—central nervous system—malignant glioma	0.00199	0.00317	CbGeAlD
Lisuride—HTR2A—brainstem—malignant glioma	0.00198	0.00315	CbGeAlD
Lisuride—ADRB1—central nervous system—malignant glioma	0.00196	0.00311	CbGeAlD
Lisuride—DRD2—midbrain—malignant glioma	0.00192	0.00304	CbGeAlD
Lisuride—HTR2A—retina—malignant glioma	0.00191	0.00304	CbGeAlD
Lisuride—HTR2B—central nervous system—malignant glioma	0.00187	0.00297	CbGeAlD
Lisuride—ADRA2C—midbrain—malignant glioma	0.00186	0.00296	CbGeAlD
Lisuride—ADRA2C—spinal cord—malignant glioma	0.00182	0.00289	CbGeAlD
Lisuride—CYP2D6—brainstem—malignant glioma	0.00181	0.00287	CbGeAlD
Lisuride—HTR2A—telencephalon—malignant glioma	0.00176	0.00279	CbGeAlD
Lisuride—Weight increased—Temozolomide—malignant glioma	0.00171	0.0236	CcSEcCtD
Lisuride—Weight decreased—Temozolomide—malignant glioma	0.0017	0.0234	CcSEcCtD
Lisuride—HTR1A—central nervous system—malignant glioma	0.00168	0.00266	CbGeAlD
Lisuride—HTR1B—brain—malignant glioma	0.00165	0.00262	CbGeAlD
Lisuride—HTR1A—cerebellum—malignant glioma	0.00164	0.0026	CbGeAlD
Lisuride—ADRA2A—medulla oblongata—malignant glioma	0.00163	0.00258	CbGeAlD
Lisuride—CYP2D6—telencephalon—malignant glioma	0.0016	0.00255	CbGeAlD
Lisuride—HTR1D—brain—malignant glioma	0.0016	0.00254	CbGeAlD
Lisuride—HTR2C—brain—malignant glioma	0.00158	0.00251	CbGeAlD
Lisuride—ADRB1—brain—malignant glioma	0.00155	0.00247	CbGeAlD
Lisuride—Hallucination—Carmustine—malignant glioma	0.00155	0.0214	CcSEcCtD
Lisuride—Oedema peripheral—Carmustine—malignant glioma	0.00153	0.0211	CcSEcCtD
Lisuride—DRD2—central nervous system—malignant glioma	0.00152	0.00241	CbGeAlD
Lisuride—Hallucination—Temozolomide—malignant glioma	0.00149	0.0206	CcSEcCtD
Lisuride—HTR2B—brain—malignant glioma	0.00149	0.00236	CbGeAlD
Lisuride—ADRA2A—midbrain—malignant glioma	0.00149	0.00236	CbGeAlD
Lisuride—DRD2—cerebellum—malignant glioma	0.00148	0.00235	CbGeAlD
Lisuride—Oedema peripheral—Temozolomide—malignant glioma	0.00148	0.0204	CcSEcCtD
Lisuride—ADRA2C—central nervous system—malignant glioma	0.00147	0.00234	CbGeAlD
Lisuride—ADRA2A—spinal cord—malignant glioma	0.00145	0.0023	CbGeAlD
Lisuride—ADRA2C—cerebellum—malignant glioma	0.00144	0.00229	CbGeAlD
Lisuride—Cardiac disorder—Temozolomide—malignant glioma	0.00139	0.0193	CcSEcCtD
Lisuride—HTR2A—medulla oblongata—malignant glioma	0.00138	0.0022	CbGeAlD
Lisuride—Angiopathy—Temozolomide—malignant glioma	0.00136	0.0188	CcSEcCtD
Lisuride—Mental disorder—Carmustine—malignant glioma	0.00136	0.0188	CcSEcCtD
Lisuride—Immune system disorder—Temozolomide—malignant glioma	0.00136	0.0187	CcSEcCtD
Lisuride—Mediastinal disorder—Temozolomide—malignant glioma	0.00135	0.0187	CcSEcCtD
Lisuride—Malnutrition—Carmustine—malignant glioma	0.00135	0.0187	CcSEcCtD
Lisuride—HTR1A—brain—malignant glioma	0.00133	0.00212	CbGeAlD
Lisuride—Mental disorder—Temozolomide—malignant glioma	0.00132	0.0182	CcSEcCtD
Lisuride—Malnutrition—Temozolomide—malignant glioma	0.00131	0.0181	CcSEcCtD
Lisuride—HTR2A—midbrain—malignant glioma	0.00126	0.00201	CbGeAlD
Lisuride—HTR2A—spinal cord—malignant glioma	0.00123	0.00196	CbGeAlD
Lisuride—DRD2—brain—malignant glioma	0.0012	0.00191	CbGeAlD
Lisuride—ADRA2A—central nervous system—malignant glioma	0.00118	0.00187	CbGeAlD
Lisuride—Vertigo—Temozolomide—malignant glioma	0.00117	0.0162	CcSEcCtD
Lisuride—ADRA2C—brain—malignant glioma	0.00117	0.00186	CbGeAlD
Lisuride—Palpitations—Temozolomide—malignant glioma	0.00116	0.016	CcSEcCtD
Lisuride—ADRA2A—cerebellum—malignant glioma	0.00115	0.00183	CbGeAlD
Lisuride—Anxiety—Carmustine—malignant glioma	0.00115	0.0159	CcSEcCtD
Lisuride—Cough—Temozolomide—malignant glioma	0.00114	0.0158	CcSEcCtD
Lisuride—Confusional state—Carmustine—malignant glioma	0.00111	0.0154	CcSEcCtD
Lisuride—Anxiety—Temozolomide—malignant glioma	0.00111	0.0153	CcSEcCtD
Lisuride—Infection—Carmustine—malignant glioma	0.0011	0.0152	CcSEcCtD
Lisuride—Dry mouth—Temozolomide—malignant glioma	0.00109	0.015	CcSEcCtD
Lisuride—Tachycardia—Carmustine—malignant glioma	0.00108	0.0149	CcSEcCtD
Lisuride—Confusional state—Temozolomide—malignant glioma	0.00108	0.0149	CcSEcCtD
Lisuride—Infection—Temozolomide—malignant glioma	0.00106	0.0146	CcSEcCtD
Lisuride—Anorexia—Carmustine—malignant glioma	0.00105	0.0145	CcSEcCtD
Lisuride—Nervous system disorder—Temozolomide—malignant glioma	0.00105	0.0145	CcSEcCtD
Lisuride—Hyperhidrosis—Temozolomide—malignant glioma	0.00103	0.0142	CcSEcCtD
Lisuride—Anorexia—Temozolomide—malignant glioma	0.00102	0.014	CcSEcCtD
Lisuride—HTR2A—central nervous system—malignant glioma	0.001	0.00159	CbGeAlD
Lisuride—Insomnia—Carmustine—malignant glioma	0.000998	0.0138	CcSEcCtD
Lisuride—Dyspnoea—Carmustine—malignant glioma	0.000984	0.0136	CcSEcCtD
Lisuride—Somnolence—Carmustine—malignant glioma	0.000981	0.0136	CcSEcCtD
Lisuride—HTR2A—cerebellum—malignant glioma	0.000978	0.00155	CbGeAlD
Lisuride—Insomnia—Temozolomide—malignant glioma	0.000965	0.0133	CcSEcCtD
Lisuride—Decreased appetite—Carmustine—malignant glioma	0.00096	0.0133	CcSEcCtD
Lisuride—Gastrointestinal disorder—Carmustine—malignant glioma	0.000953	0.0132	CcSEcCtD
Lisuride—Dyspnoea—Temozolomide—malignant glioma	0.000951	0.0131	CcSEcCtD
Lisuride—Somnolence—Temozolomide—malignant glioma	0.000948	0.0131	CcSEcCtD
Lisuride—Constipation—Carmustine—malignant glioma	0.000944	0.013	CcSEcCtD
Lisuride—ADRA2A—brain—malignant glioma	0.000934	0.00148	CbGeAlD
Lisuride—Decreased appetite—Temozolomide—malignant glioma	0.000927	0.0128	CcSEcCtD
Lisuride—CYP3A4—central nervous system—malignant glioma	0.000926	0.00147	CbGeAlD
Lisuride—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000921	0.0127	CcSEcCtD
Lisuride—Fatigue—Temozolomide—malignant glioma	0.00092	0.0127	CcSEcCtD
Lisuride—Constipation—Temozolomide—malignant glioma	0.000912	0.0126	CcSEcCtD
Lisuride—CYP2D6—central nervous system—malignant glioma	0.000911	0.00145	CbGeAlD
Lisuride—Feeling abnormal—Carmustine—malignant glioma	0.00091	0.0126	CcSEcCtD
Lisuride—CYP2D6—cerebellum—malignant glioma	0.000891	0.00141	CbGeAlD
Lisuride—Feeling abnormal—Temozolomide—malignant glioma	0.000879	0.0121	CcSEcCtD
Lisuride—HTR2A—brain—malignant glioma	0.000794	0.00126	CbGeAlD
Lisuride—Asthenia—Carmustine—malignant glioma	0.000792	0.0109	CcSEcCtD
Lisuride—Asthenia—Temozolomide—malignant glioma	0.000765	0.0106	CcSEcCtD
Lisuride—Dizziness—Carmustine—malignant glioma	0.00073	0.0101	CcSEcCtD
Lisuride—CYP2D6—brain—malignant glioma	0.000723	0.00115	CbGeAlD
Lisuride—Dizziness—Temozolomide—malignant glioma	0.000705	0.00975	CcSEcCtD
Lisuride—Vomiting—Carmustine—malignant glioma	0.000702	0.0097	CcSEcCtD
Lisuride—Headache—Carmustine—malignant glioma	0.000692	0.00955	CcSEcCtD
Lisuride—Vomiting—Temozolomide—malignant glioma	0.000678	0.00937	CcSEcCtD
Lisuride—Headache—Temozolomide—malignant glioma	0.000668	0.00923	CcSEcCtD
Lisuride—ADRA1B—Signaling by GPCR—PIK3CA—malignant glioma	2.35e-05	7.9e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	2.35e-05	7.89e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—ERBB2—malignant glioma	2.35e-05	7.89e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—AKT1—malignant glioma	2.35e-05	7.88e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MDM2—malignant glioma	2.34e-05	7.87e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—RAF1—malignant glioma	2.34e-05	7.84e-05	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—AKT1—malignant glioma	2.32e-05	7.8e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—KRAS—malignant glioma	2.32e-05	7.8e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CB—malignant glioma	2.32e-05	7.78e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—AKT1—malignant glioma	2.32e-05	7.78e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—AKT1—malignant glioma	2.32e-05	7.78e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—ERBB2—malignant glioma	2.31e-05	7.76e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—FGF2—malignant glioma	2.31e-05	7.76e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—BRAF—malignant glioma	2.31e-05	7.75e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MYC—malignant glioma	2.31e-05	7.74e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—BCHE—malignant glioma	2.31e-05	7.74e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—VEGFA—malignant glioma	2.3e-05	7.74e-05	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—AKT1—malignant glioma	2.3e-05	7.73e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CASP3—malignant glioma	2.3e-05	7.73e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CXCL8—malignant glioma	2.3e-05	7.73e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL2—malignant glioma	2.3e-05	7.72e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CXCL8—malignant glioma	2.29e-05	7.69e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—STAT3—malignant glioma	2.28e-05	7.66e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CASP3—malignant glioma	2.28e-05	7.66e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CB—malignant glioma	2.28e-05	7.66e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL2—malignant glioma	2.28e-05	7.65e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—SLC5A5—malignant glioma	2.28e-05	7.65e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—FGF2—malignant glioma	2.27e-05	7.63e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MYC—malignant glioma	2.26e-05	7.58e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—EGFR—malignant glioma	2.26e-05	7.57e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CB—malignant glioma	2.25e-05	7.56e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT2—malignant glioma	2.25e-05	7.55e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	2.24e-05	7.52e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTGS2—malignant glioma	2.23e-05	7.49e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CXCL8—malignant glioma	2.23e-05	7.48e-05	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—AKT1—malignant glioma	2.22e-05	7.47e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MYC—malignant glioma	2.22e-05	7.46e-05	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	2.21e-05	7.43e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—EGFR—malignant glioma	2.21e-05	7.41e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CASP3—malignant glioma	2.2e-05	7.4e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL2—malignant glioma	2.2e-05	7.39e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CXCL8—malignant glioma	2.19e-05	7.36e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CASP3—malignant glioma	2.19e-05	7.36e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL2—malignant glioma	2.19e-05	7.35e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MMP9—malignant glioma	2.18e-05	7.31e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—VEGFA—malignant glioma	2.17e-05	7.3e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—EGFR—malignant glioma	2.17e-05	7.3e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—PIK3CA—malignant glioma	2.17e-05	7.29e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PTEN—malignant glioma	2.16e-05	7.26e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MDM2—malignant glioma	2.16e-05	7.26e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	2.16e-05	7.25e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MMP9—malignant glioma	2.16e-05	7.24e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—RAF1—malignant glioma	2.15e-05	7.23e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—STAT3—malignant glioma	2.15e-05	7.23e-05	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—AKT1—malignant glioma	2.15e-05	7.22e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—VEGFA—malignant glioma	2.14e-05	7.2e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—VEGFA—malignant glioma	2.14e-05	7.2e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PTEN—malignant glioma	2.14e-05	7.2e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	2.14e-05	7.18e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	2.13e-05	7.17e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CASP3—malignant glioma	2.13e-05	7.16e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—ERBB2—malignant glioma	2.13e-05	7.15e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—KRAS—malignant glioma	2.13e-05	7.15e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL2—malignant glioma	2.13e-05	7.15e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MDM2—malignant glioma	2.13e-05	7.14e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—STAT3—malignant glioma	2.12e-05	7.13e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—STAT3—malignant glioma	2.12e-05	7.13e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MYC—malignant glioma	2.12e-05	7.12e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—RAF1—malignant glioma	2.12e-05	7.12e-05	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—AKT1—malignant glioma	2.12e-05	7.11e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	2.11e-05	7.1e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—AKT1—malignant glioma	2.11e-05	7.09e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CB—malignant glioma	2.1e-05	7.06e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CAV1—malignant glioma	2.1e-05	7.06e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CASP3—malignant glioma	2.1e-05	7.04e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—ERBB2—malignant glioma	2.1e-05	7.04e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL2—malignant glioma	2.09e-05	7.03e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—AKT1—malignant glioma	2.09e-05	7.02e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—AKT1—malignant glioma	2.09e-05	7.01e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—KRAS—malignant glioma	2.09e-05	7e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MMP9—malignant glioma	2.08e-05	6.99e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—EGFR—malignant glioma	2.07e-05	6.97e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MMP9—malignant glioma	2.07e-05	6.95e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PTEN—malignant glioma	2.07e-05	6.95e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	2.07e-05	6.95e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—FGF2—malignant glioma	2.07e-05	6.94e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTEN—malignant glioma	2.06e-05	6.91e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—KRAS—malignant glioma	2.05e-05	6.89e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CXCL8—malignant glioma	2.02e-05	6.79e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—malignant glioma	2.02e-05	6.78e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—malignant glioma	2.01e-05	6.76e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—malignant glioma	2.01e-05	6.74e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—malignant glioma	2e-05	6.72e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—malignant glioma	2e-05	6.72e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CXCL8—malignant glioma	1.99e-05	6.68e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—malignant glioma	1.98e-05	6.66e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—malignant glioma	1.97e-05	6.63e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—malignant glioma	1.97e-05	6.63e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—malignant glioma	1.97e-05	6.62e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—malignant glioma	1.96e-05	6.58e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	1.96e-05	6.57e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—malignant glioma	1.96e-05	6.57e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—malignant glioma	1.95e-05	6.56e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—malignant glioma	1.95e-05	6.56e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—malignant glioma	1.95e-05	6.55e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—malignant glioma	1.95e-05	6.53e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	1.94e-05	6.52e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—malignant glioma	1.94e-05	6.5e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—malignant glioma	1.93e-05	6.5e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MDM2—malignant glioma	1.93e-05	6.5e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—malignant glioma	1.93e-05	6.49e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—malignant glioma	1.93e-05	6.48e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—malignant glioma	1.93e-05	6.48e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—malignant glioma	1.93e-05	6.48e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RAF1—malignant glioma	1.93e-05	6.47e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	1.92e-05	6.46e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	1.92e-05	6.45e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—malignant glioma	1.92e-05	6.44e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—malignant glioma	1.92e-05	6.44e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—malignant glioma	1.91e-05	6.43e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	1.91e-05	6.4e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—malignant glioma	1.9e-05	6.39e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—malignant glioma	1.9e-05	6.38e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—malignant glioma	1.89e-05	6.36e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—malignant glioma	1.89e-05	6.33e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	1.88e-05	6.32e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—malignant glioma	1.87e-05	6.28e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—malignant glioma	1.86e-05	6.24e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—malignant glioma	1.85e-05	6.23e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—malignant glioma	1.85e-05	6.21e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—malignant glioma	1.85e-05	6.21e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PPARG—malignant glioma	1.85e-05	6.2e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—malignant glioma	1.84e-05	6.18e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTP1—malignant glioma	1.83e-05	6.16e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—malignant glioma	1.83e-05	6.14e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—malignant glioma	1.82e-05	6.13e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—malignant glioma	1.82e-05	6.12e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—malignant glioma	1.82e-05	6.12e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—malignant glioma	1.82e-05	6.1e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	1.81e-05	6.07e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—malignant glioma	1.81e-05	6.07e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—malignant glioma	1.8e-05	6.05e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—malignant glioma	1.8e-05	6.04e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—malignant glioma	1.8e-05	6.04e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—malignant glioma	1.79e-05	6.01e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—malignant glioma	1.79e-05	6e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAT—malignant glioma	1.78e-05	5.99e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—malignant glioma	1.78e-05	5.98e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	1.78e-05	5.98e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—malignant glioma	1.77e-05	5.95e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—malignant glioma	1.76e-05	5.92e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—malignant glioma	1.76e-05	5.91e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	1.75e-05	5.87e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—malignant glioma	1.74e-05	5.86e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—malignant glioma	1.74e-05	5.85e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—malignant glioma	1.74e-05	5.85e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—malignant glioma	1.73e-05	5.81e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—malignant glioma	1.73e-05	5.8e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—malignant glioma	1.72e-05	5.77e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—malignant glioma	1.71e-05	5.75e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—malignant glioma	1.7e-05	5.7e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—malignant glioma	1.69e-05	5.67e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NCOR1—malignant glioma	1.69e-05	5.66e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—malignant glioma	1.68e-05	5.65e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—malignant glioma	1.68e-05	5.65e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—malignant glioma	1.68e-05	5.62e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—malignant glioma	1.68e-05	5.62e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—malignant glioma	1.67e-05	5.62e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—malignant glioma	1.66e-05	5.59e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—malignant glioma	1.66e-05	5.58e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—malignant glioma	1.65e-05	5.53e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—malignant glioma	1.64e-05	5.52e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—malignant glioma	1.64e-05	5.51e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—malignant glioma	1.64e-05	5.5e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—malignant glioma	1.64e-05	5.49e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—malignant glioma	1.63e-05	5.47e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—malignant glioma	1.63e-05	5.46e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—malignant glioma	1.62e-05	5.46e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—malignant glioma	1.62e-05	5.44e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—malignant glioma	1.62e-05	5.44e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—malignant glioma	1.61e-05	5.42e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—malignant glioma	1.6e-05	5.38e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—malignant glioma	1.6e-05	5.37e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—malignant glioma	1.6e-05	5.37e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—malignant glioma	1.59e-05	5.34e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	1.59e-05	5.33e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—malignant glioma	1.58e-05	5.31e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—malignant glioma	1.57e-05	5.26e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—malignant glioma	1.54e-05	5.17e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—malignant glioma	1.54e-05	5.16e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—malignant glioma	1.53e-05	5.13e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—malignant glioma	1.51e-05	5.08e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—malignant glioma	1.51e-05	5.08e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—malignant glioma	1.51e-05	5.07e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—malignant glioma	1.49e-05	4.99e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—malignant glioma	1.48e-05	4.96e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—malignant glioma	1.48e-05	4.96e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—malignant glioma	1.47e-05	4.94e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	1.47e-05	4.93e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—malignant glioma	1.47e-05	4.93e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—malignant glioma	1.46e-05	4.91e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	1.46e-05	4.9e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—malignant glioma	1.45e-05	4.88e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—malignant glioma	1.45e-05	4.88e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—malignant glioma	1.45e-05	4.88e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	1.45e-05	4.88e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—malignant glioma	1.41e-05	4.74e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—malignant glioma	1.41e-05	4.74e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—malignant glioma	1.4e-05	4.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—malignant glioma	1.4e-05	4.68e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	1.39e-05	4.67e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—malignant glioma	1.39e-05	4.66e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—malignant glioma	1.38e-05	4.63e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAV1—malignant glioma	1.37e-05	4.61e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—malignant glioma	1.37e-05	4.61e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—malignant glioma	1.37e-05	4.61e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—malignant glioma	1.37e-05	4.6e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—malignant glioma	1.37e-05	4.6e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—malignant glioma	1.37e-05	4.59e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—malignant glioma	1.35e-05	4.54e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—malignant glioma	1.34e-05	4.52e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—malignant glioma	1.32e-05	4.44e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—malignant glioma	1.28e-05	4.3e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—malignant glioma	1.27e-05	4.26e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	1.26e-05	4.24e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.25e-05	4.2e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—malignant glioma	1.25e-05	4.19e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—malignant glioma	1.25e-05	4.19e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—malignant glioma	1.24e-05	4.16e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—malignant glioma	1.24e-05	4.15e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—malignant glioma	1.22e-05	4.1e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARG—malignant glioma	1.21e-05	4.06e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—malignant glioma	1.19e-05	4e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—malignant glioma	1.19e-05	3.98e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—malignant glioma	1.15e-05	3.88e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	1.15e-05	3.85e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—malignant glioma	1.14e-05	3.81e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—malignant glioma	1.12e-05	3.76e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—malignant glioma	1.11e-05	3.73e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.1e-05	3.69e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—malignant glioma	1.05e-05	3.52e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—malignant glioma	1.03e-05	3.46e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—malignant glioma	9.59e-06	3.22e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—malignant glioma	9.5e-06	3.19e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—malignant glioma	9.37e-06	3.15e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—malignant glioma	8.94e-06	3e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—malignant glioma	8.29e-06	2.78e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—malignant glioma	7.3e-06	2.45e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—malignant glioma	5.85e-06	1.96e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—malignant glioma	4.78e-06	1.6e-05	CbGpPWpGaD
